1038915-58-0 Usage
Description
2-4-[(3S)-piperidin-3-yl]phenyl-2H-indazole-7-carboxamide is a complex organic compound with a unique molecular structure. It is characterized by the presence of a piperidinyl group attached to a phenyl ring, which is further connected to an indazole-7-carboxamide moiety. 2-4-[(3S)-piperidin-3-yl]phenyl-2H-indazole-7-carboxamide has potential applications in various fields due to its specific structural features and interactions with biological targets.
Uses
Used in Pharmaceutical Industry:
2-4-[(3S)-piperidin-3-yl]phenyl-2H-indazole-7-carboxamide is used as a pharmaceutical compound for its potential therapeutic effects. The compound's unique structure allows it to interact with specific biological targets, making it a promising candidate for the development of new drugs.
Used in Anticancer Applications:
In the field of oncology, 2-4-[(3S)-piperidin-3-yl]phenyl-2H-indazole-7-carboxamide may be employed as an anticancer agent. Its ability to modulate various signaling pathways and target specific proteins involved in cancer cell growth and survival could make it an effective treatment option for certain types of cancer.
Used in Drug Delivery Systems:
To enhance the bioavailability and therapeutic outcomes of 2-4-[(3S)-piperidin-3-yl]phenyl-2H-indazole-7-carboxamide, it can be incorporated into novel drug delivery systems. These systems, which may include organic and metallic nanoparticles, can improve the compound's delivery to target cells and tissues, increasing its overall efficacy.
It is important to note that the specific applications and effectiveness of 2-4-[(3S)-piperidin-3-yl]phenyl-2H-indazole-7-carboxamide will depend on further research and development, as well as clinical trials to validate its safety and efficacy in humans.
Check Digit Verification of cas no
The CAS Registry Mumber 1038915-58-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,8,9,1 and 5 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1038915-58:
(9*1)+(8*0)+(7*3)+(6*8)+(5*9)+(4*1)+(3*5)+(2*5)+(1*8)=160
160 % 10 = 0
So 1038915-58-0 is a valid CAS Registry Number.
1038915-58-0Relevant articles and documents
Synthesis method for preparing PARP inhibitor Niraparib
-
, (2017/08/28)
The invention provides a novel synthesis method for preparing a PARP inhibitor Niraparib. The method comprises the steps that a starting material methyl anthranilate is subjected to diazo coupling, cyclization, amidation, BOC removal and chiral resolution, and then the Niraparib with the purity reaching 99.5% is obtained. The method is simple, convenient and easy to operate suitable for industrial production.
Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors
Jones, Philip,Altamura, Sergio,Boueres, Julia,Ferrigno, Federica,Fonsi, Massimiliano,Giomini, Claudia,Lamartina, Stefania,Monteagudo, Edith,Ontoria, Jesus M.,Orsale, Maria Vittoria,Palumbi, Maria Cecilia,Pesci, Silvia,Roscilli, Giuseppe,Scarpelli, Rita,Schultz-Fademrecht, Carsten,Toniatti, Carlo,Rowley, Michael
experimental part, p. 7170 - 7185 (2010/07/04)
We disclose the development of a novel series of 2-phenyl-2H-indazole-7- carboxamides as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors. This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells. Extrahepatic oxidation by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported. These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide 56 (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clinical trials. This compound displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range. Compound 56 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.
